Natasha Begon, ANP
NPI 1699043174 · Adult Health Nurse Practitioner · Venice, FL
Enrolled with Medicare as Order and Referring Only - Nurse Practitioner · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1699043174
- Entity type
- Individual
- Primary specialty
- Adult Health Nurse PractitionerPhysician Assistants & Advanced Practice Nursing Providers
- Credential
- ANP
- Sex
- Female
- Sole proprietor
- No
- License
- 3-002692 (AL)
Specialties & taxonomies
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure33% of score
14 yrs in NPPES registry
- Profile completeness33% of score
100% of core fields populated
- Practice footprint20% of score
1 documented practice location
- Open Payments transparency13% of score
Has Open Payments disclosures (2024)
Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 24 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Furosemide | 65 | 15 |
| Ipratropium/Albuterol Sulfatebrand: Ipratropium-Albuterol | 50 | 27 |
| Levothyroxine Sodium | 42 | — |
| Potassium Chloride | 41 | — |
| Atorvastatin Calcium | 38 | — |
| Famotidine | 37 | — |
| Pantoprazole Sodium | 30 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$125 across 1 record (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2011-12-12
- Last updated
- 2026-03-25
- Certified
- 2026-03-25
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.